Carbamoylphosphonates inhibit autotaxin and metastasis formation in vivo

References

• Stracke ML, Krutzsch HC, Unsworth EJ, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992;267:2524–9
   PubMed Web of Science ®Google Scholar
• Gijsbers R, Aoki J, Arai H, Bollen M. The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS Lett 2003;538:60–4
   PubMed Web of Science ®Google Scholar
• Stefan C, Jansen S, Bollen M. Modulation of purinergic signaling by NPP-type ectophosphodiesterases. Purinergic Signal 2006;2:361–70
   PubMedGoogle Scholar
• Tokumura A, Majima E, Kariya Y, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002;277:39436–42
   PubMed Web of Science ®Google Scholar
• Noguchi K, Herr D, Mutoh T, Chun J. Lysophosphatidic acid (LPA) and its receptors. Curr Opin Pharmacol 2009;9:15–23
   PubMed Web of Science ®Google Scholar
• Albers HM, Ovaa H. Chemical evolution of autotaxin inhibitors. Chem Rev 2012;112:2593–603
   PubMed Web of Science ®Google Scholar
• Potter CPS, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003;89:2–7
   PubMed Web of Science ®Google Scholar
• Pastorekova S, Zavadova Z, Kostal M, et al. A novel quasi-viral agent, MaTu, is a two-component system. Virology 1992;187:620–6
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Conway J. Carbonic anhydrase: its inhibitors and activators. 1st ed. Boca Raton, NY, London: CRC Press; 2004
   Google Scholar
• Cecchi A, Supuran CT. Fluorescence- and spin-labeled carbonic anhydrase inhibitors. Curr Pharm Des 2008;14:699–707
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77
   PubMed Web of Science ®Google Scholar
• Svastova E, Hulikova A, Rafajova M, et al. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett 2004;577:439–45
   PubMed Web of Science ®Google Scholar
• Lou Y, McDonald PC, Oloumi A, et al. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Cancer Res 2011;71:3364–76
   PubMed Web of Science ®Google Scholar
• Reich R, Hoffman A, Veerendhar A, et al. Carbamoylphosphonates control tumor cell proliferation and dissemination by simultaneously inhibiting carbonic anhydrase IX and matrix metalloproteinase-2. Toward nontoxic chemotherapy targeting tumor microenvironment. J Med Chem 2012;55:7875–82
   PubMed Web of Science ®Google Scholar
• Breuer E, Salomon CJ, Katz Y, et al. Carbamoylphosphonates, a new class of in vivo active matrix metalloproteinase inhibitors. 1. Alkyl- and cycloalkylcarbamoylphosphonic acids. J Med Chem 2004;47:2826–32
   PubMed Web of Science ®Google Scholar
• Reich R, Katz Y, Hadar R, Breuer E. Carbamoylphosphonate matrix metalloproteinase inhibitors 3: in vivo evaluation of cyclopentylcarbamoylphosphonic acid in experimental metastasis and angiogenesis. Clin Cancer Res 2005;11:3925–9
   PubMed Web of Science ®Google Scholar
• Frant J, Veerendhar A, Chernilovsky T, et al. Orally active, antimetastatic, nontoxic diphenyl ether-derived carbamoylphosphonate matrix metalloproteinase inhibitors. ChemMedChem 2011;6:1471–7
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161–74
   PubMed Web of Science ®Google Scholar
• Morrison CJ, Butler GS, Rodriguez D, Overall CM. Matrix metalloproteinase proteomics: substrates, targets, and therapy. Curr Opin Cell Biol 2009;21:645–53
   PubMed Web of Science ®Google Scholar
• Madan D, Ferguson CG, Lee WY, et al. Non-invasive imaging of tumors by monitoring autotaxin activity using an enzyme-activated near-infrared fluorogenic substrate. PLoS One 2013;8:e79065
   PubMedGoogle Scholar
• Jahnke W, Henry C. An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem 2010;5:770–6
   PubMed Web of Science ®Google Scholar
• Shinoda H, Adamek G, Felix R, et al. Structure–activity relationships of various bisphosphonates. Calcif Tissue Int 1983;35:87–99
   PubMed Web of Science ®Google Scholar
• Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 2005;5:786–95
   PubMed Web of Science ®Google Scholar
• McIntyre A, Patiar S, Wigfield S, et al. Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin Cancer Res 2012;18:3100–11
   PubMed Web of Science ®Google Scholar
• Stellas D, Patsavoudi E. Inhibiting matrix metalloproteinases, an old story with new potentials for cancer treatment. Anticancer Agents Med Chem 2012;12:707–17
   PubMed Web of Science ®Google Scholar
• Lia NG, Shib ZH, Tang YP, Duan JA. Selective matrix metalloproteinase inhibitors for cancer. Curr Med Chem 2009;16:3805–27
   PubMed Web of Science ®Google Scholar
• Farkas E, Katz Y, Bhusare S, et al. Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group. J Biol Inorg Chem 2004;9:307–15
   PubMed Web of Science ®Google Scholar
• Hoffman A, Stepensky D. Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit Rev Ther Drug Carrier Syst 1999;16:571–639
   PubMed Web of Science ®Google Scholar